Search Results for 'Financial Report: Merck'

Search For:
Refine by Dates:
From: To:
Refine By Content:

  • Financial Report: Merck 1Q

    April 28, 2015
    Foreign exchange and Consumer Care divestiture impact results

  • Financial Report: Merck

    February 4, 2015
    Patent expiries and divestitures impact results

  • Financial Report: Merck

    October 28, 2014
    Merck 3Q Revenues: $10.6 billion  (-4%) 3Q Earnings: $842 million (-27%) YTD Revenues: $31.8 billion (-3%) YTD Earnings: $4.6 billion (+24%) Comments: Pharmaceutical sales were $9.1 billion in the quarter, down 4%. JANUVIA/JANUMET sales wer…

  • Financial Report: Merck

    April 29, 2014
    Revenues down 4% in the quarter

  • Financial Report: Merck

    October 28, 2013
    Revenues down 4% in the quarter

  • Financial Report: Merck

    May 1, 2013
    Singulair expiry continues to impact results

  • Financial Report: Merck

    February 1, 2013
    Revenues down 5% in the quarter

  • Financial Report: Merck 3Q

    October 26, 2012
    Key products help offset August Singulair patent expiry

  • Financial Report: Merck

    July 27, 2012
    Pharma sales up 2%, hurt by Remicade settlement

  • Financial Report: Merck

    April 27, 2012
    Pharmaceuticals sales up 3%

  • Financial Report: Merck

    February 2, 2012
    Januvia, Janumet, Isentress, and Gardasil see double-digit growth

  • Financial Report: Merck 3Q11

    October 31, 2011
    Revenues up 8%

  • Financial Report: Merck 2Q

    July 30, 2010
    Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%).

  • Financial Report: Merck 1Q

    May 4, 2010
    Singulair sales were $1.2 billion (+10%). Remicade sales were $674 million (+30%).

  • Financial Report: Merck 4Q

    February 16, 2010
    Worldwide sales of Singulair were $1.3 billion in the quarter (+12%), and for the year sales were $4.7 billion (+7%).

  • Financial Report: Merck 3Q

    October 22, 2009
    Singulair sales were $1.1 billion in the quarter (+5%).

  • Financial Report: Merck 2Q

    July 21, 2009
    Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%).

  • Financial Report: Merck 1Q09

    April 21, 2009
    Worldwide sales of Singulair were $1.1 billion (-4%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $945 million (-23%).

  • Financial Report: Merck 3Q08

    October 22, 2008
    Merck 3Q Revenues: $5.9 billion (-2%) 3Q Earnings: $1.1 billion (-28%) YTD Revenues: $17.8 billion (-1%) YTD Earnings: $6.2 billion (+26%) Comments: Januvia sales were $379 million in the quarter (+105%). Sales of Isentress were $107 m…

  • Financial Report: Merck 2Q

    July 22, 2008
    Merck 2Q Revenues: $6.1 billion (-1%) 2Q Earnings: $1.8 billion (+5%) YTD Revenues: $11.9 billion (flat) YTD Earnings: $5.1 billion (+50%) Comments: Worldwide sales of Singulair were $1.1 billion in the quarter (-1%). Combined worldwid…

  • Financial Report: Merck 1Q08

    April 21, 2008
    Merck 1Q Revenues: $5.8 billion (+1%) 1Q Earnings: $3.3 billion (+94%) Comments: Worldwide sales of Singulair were $1.1 billion (+10%); Cozaar and Hyzaar sales were $847 million (+6%); Fosamax and Fosamax Plus D sales were $470 million (-37…

  • Financial Report: Merck

    January 30, 2008
    Merck 4Q07 4Q Revenues: $6.2 billion (+3%) 4Q Loss: $1.6 billion (earnings were $473.9 million in 4Q06) FY Revenues: $24.2 billion (+7%) FY Earnings: $3.3 billion (-26%) Comments: 4Q Singulair sales were up 20% to $1.2 billion and FY s…

  • Financial Report: Merck

    January 30, 2007
    Merck 4Q Revenues: $6 billion (+5%) 4Q Earnings: $473.9 million* (earnings were $1.1 billion 4Q2005) FY Revenues: $22.6 billion (+3%) FY Earnings: $4.4 billion (-4%) Comments: Singulair sales were $960 million for the quarter, up…

  • Financial Report: Merck

    July 24, 2006
    Merck 2Q Revenues: $5.8 billion (+6%) 2Q Earnings: $1.5 billion (+108%)* YTD Reveneus: $11.2 billion (+3%) YTD Earnings: $3 billion (+44%) Comments: Zocor sales were $990 million, down 14% due to loss of marketing exclusivity. Sin…

  • 1Q Financial Report: Merck

    April 20, 2006
    Merck 1Q Revenues: $5.4 billion (+1%) 1Q Earnings: $1.5 billion (+11%) Comments: Zocor and Singulair performed well in the quarter. Worldwide sales of Singulair were $801 million, up 9%. Worldwide Zocor sales were $1.1 billion, down 4%,…